Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1976 1
1977 1
1978 1
1981 2
1983 1
1984 1
1986 1
1995 1
2000 1
2001 1
2004 1
2005 3
2014 1
2015 1
2018 3
2019 3
2020 5
2021 2
2022 4
2023 3
2024 2
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Bakris GL, et al. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. JAMA. 2015. PMID: 26325557 Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions.
Andersen BM, Faust Akl C, Wheeler MA, Li Z, Diebold M, Kilian M, Rone JM, Misra A, Kenison JE, Lee JH, Lee HG, Polonio CM, Merrell D, Weiss JH, Godinez L, Piester G, Illouz T, Ye JJ, Ghia A, Martinez J, Chung EN, Srun L, Farrenkopf D, Flausino LE, Schüle AM, Sanmarco LM, Giovannoni F, Fehrenbacher L, Charabati M, Gutiérrez-Vázquez C, Cusick MM, Prabhakar PS, Bossi CC, Lapinskas E, Nowarski R, Getz G, Ligon KL, Prinz M, Chiocca EA, Reardon DA, Quintana FJ. Andersen BM, et al. Among authors: bossi cc. Nature. 2025 Aug;644(8078):1097-1106. doi: 10.1038/s41586-025-09191-9. Epub 2025 Jun 25. Nature. 2025. PMID: 40562937
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
Lanfranconi S, Scola E, Meessen JMTA, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R; Treat_CCM Investigators. Lanfranconi S, et al. Lancet Neurol. 2023 Jan;22(1):35-44. doi: 10.1016/S1474-4422(22)00409-4. Epub 2022 Nov 17. Lancet Neurol. 2023. PMID: 36403580 Free article. Clinical Trial.
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Apfelbaum AA, Morin E, Sturm D, Ayoub G, DiGiacomo J, Bahadur S, Chandarana B, Power PC, Cusick MM, Novikov D, Prabhakar P, Jones RE, Vogelzang J, Bossi CC, Malinowski S, Woodward LM, Jones TA, Jeang J, Lamson SW, Collins J, Cai KY, Jones JS, Oh S, Jeon H, Wang J, Cameron A, Rechter P, De Leon A, Murugesan K, Montesion M, Albacker LA, Ramkissoon SH, van Tilburg CM, Hardin EC, Sievers P, Sahm F, Yeo KK, Rosenberg T, Chi SN, Wright KD, Hébert S, Peck S, Picca A, Larouche V, Renzi S, Buhrlage SJ, Bale TA, Smith AA, Touat M, Jabado N, Fischer ES, Eck MJ, Baird L, Witt O, Kleinman CL, Nguyen QD, Sheer D, Alexandrescu S, Jones DTW, Ligon KL, Bandopadhayay P. Apfelbaum AA, et al. Among authors: bossi cc. Nat Commun. 2025 Jul 31;16(1):7018. doi: 10.1038/s41467-025-61820-z. Nat Commun. 2025. PMID: 40744913 Free PMC article.
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma.
Iwamoto FM, Tanguturi SK, Nayak L, Wang TJ, Desai A, Lustig RA, Bagley S, Wong ET, Hertan LM, McCluskey C, Hayden J, Muzikansky A, Nakhawa S, Japo J, Bossi CC, Meylan M, Tian Y, Barlow GL, Speliakos P, Ayoub G, Meredith DM, Ligon KL, Haas-Kogan D, Huang K, Wucherpfennig KW, Wen PY, Reardon DA. Iwamoto FM, et al. Among authors: bossi cc. Clin Cancer Res. 2025 Jan 17;31(2):316-327. doi: 10.1158/1078-0432.CCR-24-1629. Clin Cancer Res. 2025. PMID: 39513953 Clinical Trial.
44 results